HEALTH

• Researchers have discovered that genetic factors may determine why certain individuals suffer more significant brain damage from chronic sleep deprivation than others. • A preliminary study suggests that the lycopene and antioxidants in tomatoes may reduce oxidative stress and improve liver fat metabolism in people with MASLD. • The tomato study is currently limited by its small sample size and short six-week duration, meaning the results are not yet clinically definitive.

• Betting platforms Kalshi and Polymarket now allow users to wager on whether the FDA will approve treatments for lung, breast, pancreas, and blood cancers this year. • Kalshi intends to expand its offerings by allowing users to bet on the specific outcomes of clinical drug trials. • Simultaneously, the FDA has reiterated concerns regarding Replimune's lack of adequate data as the biotech company attempts for a third time to gain clearance for a controversial skin cancer drug.

• Since the initial reporting of Covid-19, medical understanding has evolved significantly regarding the virus's behavior and the effectiveness of countermeasures. • In December 2020, the US FDA granted emergency use authorization to Pfizer/BioNTech and Moderna vaccines after clinical trials demonstrated over 90% efficacy in preventing symptomatic disease. • These findings highlighted the critical role of rapid vaccine development in controlling the spread of the novel coronavirus during the height of the pandemic.

• The FDA is currently reviewing Moderna's mRNA-based flu vaccine, which would be the first of its kind to enter the commercial market. • This decision comes amid a climate of skepticism regarding mRNA technology, highlighted by questions from RFK Jr. and recent HHS funding cuts. • The regulatory uncertainty and funding drops have alarmed venture capital firms, threatening the development of mRNA therapies for Lyme disease and rare cancers.

• A new medical review suggests that reducing protein consumption may slow biological aging and extend lifespan by improving metabolism and lowering inflammation. • Research indicates that protein restriction preserves healthy cell function and reduces cellular damage, with similar benefits previously observed in flies and rodents. • Human clinical trials demonstrate that these diets can effectively reduce body weight, fat mass, and fasting blood sugar, even without overall calorie restriction.

• Helus Pharma has appointed a new CEO to lead the company as it advances its lead candidate, HLP003, toward potential commercialization. • The company announced that enrollment is now complete for the APPROACH clinical trial, with topline data expected to be released in Q4 2026. • Enrollment remains ongoing for the EMBRACE trial, as the company works to confirm the effectiveness and safety of the treatment in large patient groups.

• The Department of Veterans Affairs is launching a randomized clinical trial to determine if GLP-1 drugs can reduce alcohol abuse among U.S. military veterans. • The study will specifically measure whether semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, can decrease drinking and improve overall quality of life. • This initiative targets a significant public health need, as an estimated 400,000 U.S. veterans are currently diagnosed with alcohol use disorder.

• New research indicates that individuals using cannabis for self-medication face increased risks of paranoia and typically consume higher levels of THC. • The study highlights that childhood trauma further amplifies these psychological risks, creating a more dangerous interaction for vulnerable users. • These findings are critical as they challenge the perceived safety of self-treating mental health issues with cannabis without professional guidance.

• COVID-19 dominated the global landscape throughout 2020, evolving from an emerging health crisis to a pandemic that concluded the year with the arrival of vaccines. • Overwhelmed hospitals struggled with severe resource shortages, specifically lacking enough personal protective equipment (PPE) to maintain standard operations. • The crisis delayed the start of new clinical trials and hindered the launch of recently FDA-approved drugs, as medical facilities prioritized emergency care over new treatments.

• The Trump Administration and the Department of Health and Human Services (HHS) have released the "United States Government Policy for Stopping High-Risk Life Sciences Research." • This new framework explicitly prohibits federally supported gain-of-function research that is deemed dangerous to public health. • The policy aims to enhance oversight for life sciences research that could potentially compromise biosecurity or national security.

• An FDA advisory panel voted on Thursday to support trial results for Replimune's drug, RP1, which targets a specific type of skin cancer. • The FDA had previously declined to approve RP1 twice, most recently in April, due to a lack of a control group and insufficient evidence of effectiveness. • This panel's endorsement provides critical momentum for the drug's approval process after the agency demanded more comprehensive data.

• A Cyclosporiasis outbreak has been reported across 17 states, with 145 confirmed cases of the gastrointestinal disease caused by the Cyclospora parasite. • The CDC has issued an alert to health care workers to ensure rapid diagnosis and proper response, as the infection spreads via contaminated food or water. • This outbreak is critical for infection prevention and control (IPC) teams to manage, as timely identification is necessary to protect patients and contain the spread.

• The U.S. is seeing a surge in vaccine policy activity, with over 400 state vaccine bills introduced and nine new laws enacted. • New federal charters have been established through July 2028, focusing on healthy lifestyle initiatives, dietary supplements, and FDA-approved off-label drug use. • To ensure impartiality, the charter mandates that members from academia with pharmaceutical funding cannot exceed one-third of the committee, while public members must comprise at least one-third.

• An FDA advisory panel voted 10-3 on Thursday in favor of Replimune Group's experimental melanoma treatment, RP1. • The committee concluded that efficacy results from the company's IGNYTE clinical trial were both evaluable and clinically meaningful. • This positive recommendation significantly increases the likelihood of FDA approval following two previous rejections of the therapy.

• A new AI tool called MEDWACS has been developed to identify undiagnosed individuals with type 2 diabetes using over 30 years of U.S. health data. • The findings, published in the Journal of Clinical Epidemiology, highlight the tool's ability to detect the disease before patients seek medical testing. • Early detection is critical because unnoticed diabetes significantly increases the risk of kidney failure, vision loss, and heart disease.

• The nominee for the director of the Centers for Disease Control and Prevention (CDC) has advanced to a full Senate vote. • The federal government indicated that Medicaid work requirements will not be delayed, maintaining current policy timelines. • These developments signal a shift in public health leadership and a commitment to stricter eligibility criteria for healthcare assistance.

• An infectious disease specialist is debunking common misconceptions about measles as U.S. cases reach a 35-year high. • The doctor draws on professional experience treating patients during the 2014-2015 Disneyland outbreak, which spread across six U.S. states and into Canada. • This effort highlights the ongoing risk of preventable crises and the critical need for public health literacy to combat misinformation.

• An FDA advisory committee has voted in favor of RP1, an experimental melanoma drug developed by Replimune, despite the therapy being rejected in April. • The decision comes during a review meeting where experts evaluated the drug's efficacy and safety for treating melanoma patients. • This endorsement marks a significant reprieve for Replimune, potentially reversing a previous regulatory setback under new FDA leadership.